Table 3.
Dose response assays for assessing synergy between two targeted therapy drugs drug A (poziotinib (Pozi)) and drug B (niraparib (Nira))
| Tested drug A concentration | Pozi 0.4 nM | Pozi 1 nM | Pozi 2 nM | Pozi 4 nM | |
|---|---|---|---|---|---|
| Nira 0 Pozi 0 |
Nira 0 Pozi 4 nM |
Nira 0 Pozi 10 nM |
Nira 0 Pozi 20 nM |
Nira 0 Pozi 40 nM |
Tested drug B concentration |
| Nira 4 nM Pozi 0 |
Nira 4 nM Pozi 4 nM |
Nira 4 nM Pozi 10 nM |
Nira 4 nM Pozi 20 nM |
Nira 4 nM Pozi 40 nM |
Nira 0.4 nM |
| Nira 10 nM Pozi 0 |
Nira 10 nM Pozi 4 nM |
Nira 10 nM Pozi 10 nM |
Nira 10 nM Pozi 20 nM |
Nira 10 nM Pozi 40 nM |
Nira 1 nM |
| Nira 20 nM Pozi 0 |
Nira 20 nM Pozi 4 nM |
Nira 20 nM Pozi 10 nM |
Nira 20 nM Pozi 20 nM |
Nira 20 nM Pozi 40 nM |
Nira 2 nM |
| Nira 40 nM Pozi 0 |
Nira 40 nM Pozi 4 nM |
Nira 40 nM Pozi 10 nM |
Nira 40 nM Pozi 20 nM |
Nira 40 nM Pozi 40 nM |
Nira 4 nM |
The working concentrations of Pozi or Nira are listed based on the utilization of 10 μL from a 10× stock concentration to achieve the final 1× concentration in a total of 100 μL per well.